In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Chiron refuses $4.5bn Novartis offer, later accepts $5.1bn

Executive Summary

Stating that the offer is "inadequate," Chiron has refused Novartis's proposal to buy the 57.8% of Chiron (112mm fully diluted common shares) it doesn't already own. The offer was $40 cash per share (a 12% premium), for a total of $4.5bn.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Acquisition
    • Includes Contract
    • Partial Acquisition
    • Payment Includes Cash for Equity

Related Companies